Pharmacokinetics and pharmacodynamics of the diuretic bumetanide in the elderly. 1995

R Oberbauer, and P Krivanek, and K Turnheim
Abteilung für Pharmakokinetik, Universität Wien, Austria.

In a cross-sectional study of the pharmacokinetics and pharmacodynamics of peroral and intravenous bumetanide (0.5 mg, single dose), total and renal clearance of the diuretic was significantly lower in elderly persons than in young adults, resulting in higher bumetanide plasma levels in the aged. Nonrenal clearance, bioavailability, and the volume of distribution were not significantly changed. Together with the decreased delivery into the urine the diuretic and natriuretic effect of bumetanide was reduced in the elderly. Renal clearance of bumetanide was linearly related with creatinine clearance, hence the decreases in bumetanide clearance and diuretic efficacy in the elderly are attributed to the age-dependent decline in renal function. The bumetanide concentration in urine and the fractional sodium excretion were not different in the two age groups, suggesting that the decrease in diuretic response in the elderly is a result of a reduction in the number of functioning nephrons, whereas the response of the remaining nephrons to bumetanide is unaltered.

UI MeSH Term Description Entries
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D007668 Kidney Body organ that filters blood for the secretion of URINE and that regulates ion concentrations. Kidneys
D008297 Male Males
D008657 Metabolic Clearance Rate Volume of biological fluid completely cleared of drug metabolites as measured in unit time. Elimination occurs as a result of metabolic processes in the kidney, liver, saliva, sweat, intestine, heart, brain, or other site. Total Body Clearance Rate,Clearance Rate, Metabolic,Clearance Rates, Metabolic,Metabolic Clearance Rates,Rate, Metabolic Clearance,Rates, Metabolic Clearance
D011188 Potassium An element in the alkali group of metals with an atomic symbol K, atomic number 19, and atomic weight 39.10. It is the chief cation in the intracellular fluid of muscle and other cells. Potassium ion is a strong electrolyte that plays a significant role in the regulation of fluid volume and maintenance of the WATER-ELECTROLYTE BALANCE.
D001806 Blood Urea Nitrogen The urea concentration of the blood stated in terms of nitrogen content. Serum (plasma) urea nitrogen is approximately 12% higher than blood urea nitrogen concentration because of the greater protein content of red blood cells. Increases in blood or serum urea nitrogen are referred to as azotemia and may have prerenal, renal, or postrenal causes. (From Saunders Dictionary & Encyclopedia of Laboratory Medicine and Technology, 1984) BUN,Nitrogen, Blood Urea,Urea Nitrogen, Blood
D002034 Bumetanide A sulfamyl diuretic. Bumedyl,Bumethanide,Bumex,Burinex,Drenural,Fordiuran,Miccil,PF-1593,PF 1593,PF1593
D003430 Cross-Sectional Studies Studies in which the presence or absence of disease or other health-related variables are determined in each member of the study population or in a representative sample at one particular time. This contrasts with LONGITUDINAL STUDIES which are followed over a period of time. Disease Frequency Surveys,Prevalence Studies,Analysis, Cross-Sectional,Cross Sectional Analysis,Cross-Sectional Survey,Surveys, Disease Frequency,Analyses, Cross Sectional,Analyses, Cross-Sectional,Analysis, Cross Sectional,Cross Sectional Analyses,Cross Sectional Studies,Cross Sectional Survey,Cross-Sectional Analyses,Cross-Sectional Analysis,Cross-Sectional Study,Cross-Sectional Surveys,Disease Frequency Survey,Prevalence Study,Studies, Cross-Sectional,Studies, Prevalence,Study, Cross-Sectional,Study, Prevalence,Survey, Cross-Sectional,Survey, Disease Frequency,Surveys, Cross-Sectional
D005260 Female Females
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes

Related Publications

R Oberbauer, and P Krivanek, and K Turnheim
February 1983, British journal of clinical pharmacology,
R Oberbauer, and P Krivanek, and K Turnheim
August 1982, Journal of pharmacokinetics and biopharmaceutics,
R Oberbauer, and P Krivanek, and K Turnheim
February 1974, Clinical pharmacology and therapeutics,
R Oberbauer, and P Krivanek, and K Turnheim
November 1998, Journal of clinical pharmacology,
R Oberbauer, and P Krivanek, and K Turnheim
March 2007, Clinical advances in hematology & oncology : H&O,
R Oberbauer, and P Krivanek, and K Turnheim
February 1986, Australian family physician,
R Oberbauer, and P Krivanek, and K Turnheim
November 1976, Irish medical journal,
R Oberbauer, and P Krivanek, and K Turnheim
August 1993, Biopharmaceutics & drug disposition,
R Oberbauer, and P Krivanek, and K Turnheim
December 1992, The Journal of pediatrics,
R Oberbauer, and P Krivanek, and K Turnheim
March 1999, Nihon Ronen Igakkai zasshi. Japanese journal of geriatrics,
Copied contents to your clipboard!